Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma

The aldose reductase inhibitor Fidarestat has been noted to have efficacy in treating a variety of tumors. To define its role in hepatocellular carcinoma (HCC), we induced a HCC xenograft model in mice, which were treated with different doses of Fidarestat. The amounts of natural killer (NK) cells a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tiangen Wu, Yang Ke, Haoran Tang, Chen Liao, Jinze Li, Lin Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2021-12-01
Edice:	Molecular Therapy: Oncolytics
Témata:	Fidarestat AKR1B10 natural killer cells hepatocellular carcinoma glycolysis tumor microenvironment
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S237277052100084X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!